Safety Study of TAK-700 in Subjects With Prostate Cancer.
Public ClinicalTrials.gov record NCT00569153. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1/2, Open-Label, Multiple-Dose Study of the Safety, Tolerability, and Pharmacokinetics of TAK-700 in Metastatic, Androgen-Independent Prostate Cancer Subjects
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to determine the safety and tolerability of TAK-700 in patients with asymptomatic metastatic, androgen independent prostate cancer.
Study identification
- NCT ID
- NCT00569153
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Enrollment
- 123 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Male
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 31, 2008
- Primary completion
- Dec 31, 2012
- Completion
- Jan 31, 2013
- Last update posted
- Apr 3, 2016
2008 – 2013
United States locations
- U.S. sites
- 19
- U.S. states
- 6
- U.S. cities
- 11
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| USC Westside Prostate Cancer Center | Beverly Hills | California | — | — |
| University of Southern California | Los Angeles | California | 90048 | — |
| The Angeles Clinic and Research Institute | Los Angeles | California | — | — |
| USC Norris Comprehensive Cancer Center | Los Angeles | California | — | — |
| South Florida Medical Research | Aventura | Florida | — | — |
| Florida Cancer Specialists | Fort Myers | Florida | — | — |
| Northwestern University Medical Center | Chicago | Illinois | 60611 | — |
| University of Chicago | Chicago | Illinois | 60637 | — |
| University of Chicago Comprehensive Cancer Center | Chicago | Illinois | — | — |
| University of Chicago Pharmacy | Chicago | Illinois | — | — |
| Evanston Hospital | Evanston | Illinois | — | — |
| Kellogg Pharmacy - Evanston Hospital | Evanston | Illinois | — | — |
| NorthShore University HealthSystem | Evanston | Illinois | — | — |
| Kellogg Cancer Care Center | Glenview | Illinois | — | — |
| Hematology/Oncology Associates of Central New York | East Syracuse | New York | — | — |
| Gabrail Cancer Center | Canton | Ohio | — | — |
| Cleveland Clinic | Cleveland | Ohio | 44195 | — |
| Taussig Cancer Institute | Cleveland | Ohio | — | — |
| Tennessee Oncology | Nashville | Tennessee | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00569153, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 3, 2016 · Synced Sep 5, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00569153 live on ClinicalTrials.gov.